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Introduction: Hormone receptor (HR) status has become an established target in treatment strategies of breast
cancer. Population-based estimates of contralateral breast cancer (CBC) incidence by HR subtype in particular are
limited. The aim of this study was to provide detailed data on CBC incidence for Germany.
Methods: Invasive breast cancer data were extracted on 49,804 women yielding 594 second primaries from the
cancer registries of the Federal States of Brandenburg and Saarland and the area of Munich for the period from
1998 to 2007. Multiple imputation was used on missing values for HR status. We estimated standardized incidence
ratios (SIRs) with 95% confidence intervals (95%CIs).
Results: SIR estimates of CBC among women diagnosed with an invasive first primary breast cancer (FBC) of any
HR subtype ranged from 1.0 to 1.5 in the three registries. Pooling three registries’ data, the SIR of HR-positive CBC
was 0.7 (95%CI: 0.6 to 0.8) among women with HR-positive FBC. For those women with HR-negative FBC, the SIR
of HR-negative CBC was 8.9 (95%CI: 7.1 to 11.1). Among women with FBC diagnosed before the age of 50 years,
incidence of CBC was increased, especially for HR-negative FBC (SIR: 9.2; 95%CI: 7.1 to 11.9).
Conclusions: HR status of the first primary and age at first diagnosis is relevant for predicting risk of CBC.
Particularly, patients with HR-negative FBC had elevated risks.Introduction
Prognosis of breast cancer has improved over the recent
decades by progress in diagnosis and treatment [1].
However, patients with breast cancer have an increased
risk of developing a new primary breast cancer in the
contralateral breast. Family history of breast cancer, early
age at diagnosis, characteristics of the first primary (for
example lobular histology and stage) and mutations in
specific genes, including BRCA1, BRCA2 and CHEK2,
are considered as risk factors [2,3]. Hormone receptor
(HR) status of breast cancer is also a relevant factor, in
particular with regard to treatment decisions and further
prognosis. Treatment strategies of radiotherapy and che-
motherapy after surgery of HR-positive breast cancer are* Correspondence: carsten.rusner@medizin.uni-halle.de
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unless otherwise stated.followed by an adjuvant hormonal treatment. Hormone
treatment with tamoxifen or aromatase inhibitor anastro-
zole for reducing the risk of contralateral breast cancer
(CBC) is well known. A meta-analysis of 55 randomized
trials found that use of tamoxifen for five years reduces
the risk of CBC by 47% [4]. There is some evidence that
tamoxifen treatment may increase the risk of HR-negative
CBC [5].
Only few population-based reports showed the impact
of HR subtype in invasive first primary breast cancers
(FBC) on risk of CBC. Three previously published studies
reported an increased risk of HR-negative CBC after HR-
negative FBC. Results of developing CBC after HR-positive
FBC were contradictory [6-8].
The aim of our study was to provide detailed estimates
of CBC incidence according to HR status of FBC using
data from population-based cancer registries in Germany.
This study also focused on mixed HR status, which has
not been presented by previous studies.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Female patients diagnosed with FBC were identified in
the population-based cancer registries of the Federal
States of Saarland and Brandenburg and in the Munich
Cancer Registry for the period 1998 to 2007. Ethical
approval for this study was not required because we
used anonymized data of cancer registries for scientific
purposes according to Good Practice for Secondary Data
Analysis [9].
The cancer registry of the Federal State of Brandenburg
(BB) was established in 1993 and comprises five hospital-
based cancer registries covering the entire territory of the
Federal State. The Munich Cancer Registry (MCR) was
established in 1978 and routinely records data for all can-
cer patients treated in Munich and the surrounding area.
It receives clinical data from 73 hospitals and several hun-
dred doctors in private practice. The Saarland Cancer
Registry (SL) is a population-based cancer registry and
covers the entire territory of the Federal State of Saarland.
The registry was established in 1967. The three registries
comprise a population of 6.9 million in total (BB: 2.6,
MCR: 3.3, SL: 1.1 million). BB, MCR and SL have been
involved in several regional, national and international
research collaborations [10]. The registries provide cancer
incidence data with an estimated completeness of 90%
and more [11]. However, the completeness of HR status
registration was too low for a meaningful data analysis
until 1998 because German cancer registries do not rou-
tinely collect or receive data of hormone receptor status.
A special data collection effort from available pathology
reports in all three registries allowed us to obtain HR
status information for the specified years of 1998 to 2007.
For the remaining cases with missing information on HR
status, we re-contacted the reporting pathologists.
Invasive breast cancers were coded as C50 according
to the 10th edition of the International Classification of
Diseases, respectively (ICD-10) [12]. For additional ana-
lyses, we defined four major histologic groups of breast
cancer: invasive ductal (8500/3, 8503/3, 8521/3, 8525/3),
invasive lobular (8520/3), invasive ductal and lobular mixed
(8522-8524/3, 8541/3) carcinomas, and cancers of other or
unspecified (8000/3-8004/3) histologic type based on the
3rd edition of the International Classification of Diseases
for Oncology (ICD-O-3) [13]. All patients with FBC
were followed from the date of diagnosis until detection
of a second primary cancer in the contralateral breast,
death, loss to follow-up or until 31 December 2007,
whichever of these events came first. Invasive primary
cancers occurring six months after diagnosis of the FBC
were defined as metachronous tumors. Cancers occur-
ring earlier than six months were considered as syn-
chronous tumors and were excluded from analyses.
Information on human epidermal growth factor receptor
2 (HER2) amplification, stage at time of diagnosis andtreatment was too frequently missing for a meaningful
data analysis.
Table 1 presents an overview of the analyzed FBC
cases in the registries. The proportion of histological
verification of FBC was generally high with a range of
92.5 to 96.8% and for cases of metachronous primary
breast cancer with up to 100% confirmation. The propor-
tion of missing HR status information (estrogen receptor
(ER) or progesterone receptor (PR)) in FBC ranged
between 7.0 and 15.1%. SL did not routinely collect HR
status of CBC, which was reflected in a greater proportion
of missing information. Pooling three registries’ data, the
median follow-up period for FBC was approximately just
three years. The cohort yielded a total of 180,768 person-
years of observation. We defined the following categories
of HR subtype: positive (ER+ PR+), negative (ER-PR-) and
mixed (ER+ PR- or ER-PR+).
Statistical methods
As simulation studies previously showed that analyses
using completed data sets derived from multiple imput-
ation tend to provide less biased estimates compared to
complete case analyses, we used multiple imputation of
HR status to account for missing data [14,15]. We as-
sumed missingness at random and included date of diag-
nosis, date of birth, duration of follow-up, region code
and diagnosis confirmation as additional clinical items for
the imputation. We imputed 20 times applying PROC MI
of SAS™ (SAS Inc., Cary, NC, USA). The results from
these 20 imputed data sets were summarized using
Rubin’s method [16].
We estimated the standardized incidence ratios (SIRs)
of metachronous primary breast cancer to quantify the
relative risk of CBC among women with FBC compared
to the relative risk of developing FBC in the general
population. The SIR was obtained as the ratio of the
number of observed cases (O) to the number of expected
cases (E). E was calculated by multiplying accumulated
person-years at risk after FBC and cancer incidence rates
specific for sex (female), age (0 to 4, 5 to 9, …, 80 to 84,
85+ years), five-year calendar period and the respective
registry. Corresponding 95% confidence intervals (95%
CIs) were based on the Poisson distribution. To obtain
more precise SIR estimates of metachronous primary
breast cancers, we pooled the case files and correspond-
ing person-years at risk of the registries.
Results
A total of 594 new CBCs among 49,804 women diagnosed
with FBC were registered in the three populations from
1998 through 2007. The SIRs of CBC among women with
FBC of any HR subtype ranged from 1.0 in MCR to 1.5 in
BB (Table 2). In all three registries, among women with
HR-positive FBC, risk of HR-positive CBC was lower
Table 1 Baseline characteristics of invasive breast cancer of analyzed cancer registries in Germany, 1998 to 2007
Brandenburg Munich Saarland Pooled
Registered cases of invasive first primary breast cancer (n) 15,226 26,315 8,263 49,804
Histological verification (%) 94.6 92.5 96.8 93.8
Receptor status information (%)
Estrogen positive 72.1 72.6 69.0 71.9
negative 20.9 13.5 16.0 16.2
missing 7.0 13.9 15.0 11.9
Progesterone positive 66.6 68.8 61.0 66.9
negative 26.1 17.0 23.9 20.9
missing 7.3 14.2 15.1 12.2
Median (IQR) age at diagnosis of first primary breast cancer 63 (52-72) 63 (53-73) 64 (54-74) 63 (53-73)
Person-years of observation 57,108 92,247 31,413 180,768
Median (IQR) years of follow-up 3.3 (1.3-5.9) 3.0 (1.1-5.4) 3.4 (1.3-6.0) 3.1 (1.2-5.7)
Registered cases of metachronous contralateral breast cancer (n) 185 287 122 594
Histological verification (%) 98.4 100.0 99.2 99.3
Receptor status information (%)
Estrogen positive 53.0 61.0 37.7 53.7
negative 42.7 27.2 19.7 30.5
missing 4.3 11.8 42.6 15.8
Progesterone positive 44.3 53.3 27.9 45.3
negative 51.4 34.8 29.5 38.9
missing 4.3 11.8 42.6 15.8
IQR: interquartile range.
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population. Conversely, those with HR-negative FBC had
in particular an increased risk of HR-negative CBC. SIR
estimates for HR-mixed second primary after HR-mixed
FBC were elevated in all three registries. Table 2 shows
subtype-specific SIRs for the registries that include at least
five cases in total. In sensitivity analyses, where we only
distinguished between ER-positive and ER-negative re-
gardless of the PR subtype or excluded cases with missing
HR status to assess whether imputation affected SIRs, esti-
mates were similar (Table S1 and Table S2 in Additional
file 1).
Pooling three registries’ data, the SIR of HR-positive
CBC was 0.9 (95%CI: 0.8 to 1.0). Particularly, among
women with HR-positive FBC the SIR was 0.7 (95%CI:
0.6 to 0.8). In contrast, women with FBC of any HR sub-
type showed an increased estimate of HR-negative CBC
(SIR: 2.5; 95%CI: 2.1 to 2.9). Especially, an almost nine-
fold markedly elevated incidence of CBC was observed
when FBC was HR-negative (SIR: 8.9; 95%CI: 7.1 to
11.1). Among patients with HR-mixed FBC risk of HR-
mixed CBC was increased (SIR: 4.2; 95%CI: 2.8 to 5.9).
Considering a greater proportion of missing HR status
information of CBC in SL, we restricted the pooling toBB and MCR for sensitivity. In this analysis, estimates
remained similar (results not shown).
According to the HR status and age at first cancer
diagnosis (Table 3), for women aged lower than 50 years
with HR-positive FBC, SIR of HR-positive CBC was 1.7
(95%CI: 1.2 to 2.5) while in women aged 50 years and
older that risk was lower (SIR: 0.6; 95%CI: 0.5 to 0.7)
compared to the risk of developing FBC in the general
population. We observed exceedingly pronounced risks
of CBC for women with HR-negative FBC diagnosed
before the age of 50 years (SIR: 9.2; 95%CI: 7.1 to 11.9).
Regarding these patients, the risk of HR-negative CBC
was approximately 10 times higher than that one of
HR-positive CBC.
A histology-specific analysis of FBC revealed that
estimates of HR-positive CBCs were similar: ductal (SIR:
0.8; 95%CI: 0.7 to 0.9); lobular (SIR: 0.9; 95%CI: 0.7 to
1.2). The estimated SIR for HR-negative CBC was higher
in invasive ductal (SIR: 2.7; 95%CI: 2.3 to 3.2) than in
invasive lobular (SIR: 1.6; 95%CI: 0.9 to 2.6) FBCs.
Discussion
We showed by German population-based data that
the incidence of a subsequent CBC was modified by HR
Table 2 Standardized incidence ratios of metachronous contralateral breast cancer stratified by hormone receptor
(HR)-status in Brandenburg, Munich and Saarland, 1998 to 2007
Brandenburg Munich Saarland Pooled
O SIR 95%CI O SIR 95%CI O SIR 95%CI O SIR 95%CI
Any first primary 15,226 26,315 8,263 49,804
Any second primary 185 1.5 1.3-1.7 287 1.0 0.9-1.1 122 1.4 1.2-1.7 594 1.2 1.1-1.3
Second primary HR-positive 71 0.9 0.7-1.2 137 0.8 0.6-0.9 33 1.1 0.9-1.4 241 0.9 0.8-1.0
Second primary HR-negative 68 3.3 2.6-4.2 62 2.1 1.6-2.7 23 2.3 1.5-3.2 153 2.5 2.1-2.9
Second primary HR-mixed 38 1.9 1.4-2.6 54 1.8 1.3-2.3 14 2.0 1.2-2.9 106 2.0 1.7-2.4
First primary HR-positive 9,698 17,286 4,880 31,864
Any second primary 97 1.1 0.9-1.4 149 0.8 0.6-0.9 53 1.0 0.8-1.4 299 0.9 0.8-1.0
Second primary HR-positive 44 0.8 0.6-1.0 94 0.6 0.5-0.7 26 0.9 0.6-1.2 164 0.7 0.6-0.8
Second primary HR-negative 31 2.1 1.4-3.0 17 0.8 0.5-1.2 2 50 1.1 0.8-1.4
Second primary HR-mixed 19 1.3 0.8-2.0 24 1.0 0.6-1.5 6 1.1 0.5-2.1 49 1.2 0.9-1.6
First primary HR-negative 2,731 2,758 1,164 6,653
Any second primary 61 3.0 2.3-3.9 69 2.7 2.1-3.4 34 3.2 2.2-4.5 164 2.8 2.4-3.3
Second primary HR-positive 20 1.6 1.0-2.4 17 1.0 0.6-1.5 2 39 1.1 0.8-1.5
Second primary HR-negative 31 8.5 5.8-12.0 30 8.9 6.1-12.7 18 9.6 5.8-14.9 79 8.9 7.1-11.1
Second primary HR-mixed 7 2.4 1.0-4.8 14 4.3 2.4-7.1 3 24 3.7 2.5-5.2
First primary HR- mixed 1,682 2,524 969 5,175
Any second primary 26 1.8 1.2-2.7 33 1.2 0.8-1.7 17 1.4 0.8-2.3 76 1.4 1.1-1.8
Second primary HR-positive 7 0.8 0.3-1.6 9 0.5 0.3-0.9 1 17 0.6 0.4-0.9
Second primary HR-negative 6 2.5 0.9-5.4 8 2.5 1.1-4.8 2 16 2.2 1.3-3.5
Second primary HR-mixed 12 5.0 2.6-8.7 11 3.2 1.7-5.7 4 27 4.2 2.8-5.9
O: observed number of cases; SIR: standardized incidence ratio; 95%CI: 95% confidence interval; HR, hormone receptor.
Table 3 Standardized incidence ratios of metachronous contralateral breast cancer stratified by hormone receptor
(HR)-status and age in Brandenburg, Munich and Saarland overall, 1998 to 2007
Women with first primary age <50 Women with first primary age ≥50
O SIR 95%CI O SIR 95%CI
Any first primary 9,684 40,120
Any second primary 144 4.0 3.4-4.7 450 1.0 0.9-1.1
First primary HR-positive 6,129 25,735
Any second primary 51 2.2 1.7-2.9 248 0.8 0.7-0.9
Second primary HR-positive 25 1.7 1.2-2.5 139 0.6 0.5-0.7
Second primary HR-negative 7 1.8 0.8-3.5 43 1.0 0.8-1.4
Second primary HR-mixed 11 4.8 2.5-8.4 38 1.0 0.7-1.4
First primary HR-negative 1,895 4,758
Any second primary 60 9.2 7.1-11.9 104 2.0 1.7-2.5
Second primary HR-positive 8 2.6 1.4-4.5 31 0.9 0.7-1.3
Second primary HR-negative 33 25.4 17.6-35.4 46 6.1 4.5-8.1
Second primary HR-mixed 12 18.1 9.6-31.1 12 2.3 1.3-3.7
O: observed number of cases; SIR: standardized incidence ratio; 95%CI: 95% confidence interval; HR, hormone receptor.
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tive CBC among women with HR-positive FBC while
in women with HR-negative FBC the SIR of HR-nega-
tive CBC was considerably increased. Among women
with first primary cancer diagnosed before the age of
50 years, the estimate of developing CBC was increased,
and this increase was especially pronounced in HR-
negative FBC.
As reported by previous studies, the HR status of CBC
can be more similar to the HR status of FBC than would
be expected by chance due to host factors. That leads to
the assumption that particular women are more likely to
have cancers of a certain HR subtype [17,18]. The con-
cordance in HR subtype may be the result of common
genetic and non-genetic factors that influenced the de-
velopment of FBC of a particular HR subtype as well as
the second primary occurrence of the same subtype in
the contralateral breast [19].
Our results are in accordance to previous population-
based studies that reported SIRs from about 5 to 10 for
developing HR-negative CBC among women with HR-
negative first primary [6-8]. On the one hand, limited
relative effectiveness of chemotherapy and radiotherapy,
and limited understanding of relevant targets in treat-
ment of HR-negative breast cancer may have led to that
particularly increased risk [20]. On the other hand, genetic
and non-genetic factors causing HR-negative primaries
may be relatively stronger compared to host factors caus-
ing HR-positive primaries.
With reference to previously published studies, results of
developing HR-positive CBC after HR-positive FBC remain
contradictory. While Kurian et al. and Sandberg et al.
reported increased SIRs, the study of Bouchardy et al. and
ours observed decreased SIRs [6-8]. That decrease may
reasonably be linked to adjuvant hormonal treatment used
among women with HR-positive FBC. It is well known
that hormone treatment with tamoxifen reduces the risk
of CBC [4,21,22]. This protective effect may affect cells
with carcinogenic potential in the contralateral breast.
Tamoxifen treatment was introduced in German guide-
lines in 1995. An unselected retrospective cohort study
including 2,600 breast cancer patients with universal
coverage in the catchment area of the Federal State of
Baden-Württemberg over a 13-year observation period
(1992 to 2005) reported that around 90% of endocrine-
responsive patients received an adjuvant hormonal
treatment since 1999 [23]. Our observations provide no
strong evidence that tamoxifen treatment may increase
the risk of HR-negative CBC after HR-positive FBC [5].
The increased SIR of developing HR-positive CBC after
HR-positive FBC reported by Kurian et al. may reflect
the disparities in the ability to afford hormone treatment
of different ethnic groups in the U.S. [6]. The result of
Sandberg et al. analyzing the period 1976 to 2005 may bedue to the established use of tamoxifen treatment only in
the last decade of observation [8].
In this study, approximately 10% of FBC had mixed
HR status. Women with HR-mixed FBC showed an in-
creased risk of CBC overall, and especially of HR-mixed
CBC. Although hormone treatment with tamoxifen is
used to treat both subtypes (ER+ PR- and ER-PR+), it
tends to be less effective for ER-PR+. ER status seems to
be the only factor importantly predictive for reductions
of breast cancer recurrence and death [24]. Furthermore,
Arpino et al. assumed that lack of PR in ER-positive
breast cancer may be an indicator of abnormal growth
factor signaling, which could add to resistance in tamoxifen
treatment. They noticed a poorer survival in tamoxifen-
treated women with ER+ PR- than in such women with
ER+ PR+. Our finding of an increased risk of CBC after
HR-mixed FBC may implicate those aspects [25].
Early age at first diagnosis is a well-known risk factor
for CBC [2]. It has been also reported in the context of
a positive family history of breast cancer and among
BRCA1 and BRCA2 mutation carriers [26,27]. This sug-
gests that more genetic than non-genetic factors may
contribute to these cases and women may be more sus-
ceptible to cancer developing in both breasts. In particu-
lar, we showed a markedly increased risk of HR-negative
CBC in women with age lower than 50 years, which is in
line with reports that observed that the majority of
BRCA-associated breast cancers were HR-negative and
concordant in first and second primary [28-30].
The pooling of the cancer registries’ data enabled us to
estimate SIRs of CBC in detail. Nevertheless, there are
factors limiting the interpretation of our results. First,
although this study provides the largest number of FBC
patients at risk for CBC by HR status in Europe, we still
suffer from small numbers of CBC, especially in detailed
analysis by HR subtype. Second, the median years of
follow-up of about three years seems to be short. How-
ever, previous studies showed no effect for time since
primary diagnosis on risk for CBC by HR status [6,8].
Third, there is a lack of stage and treatment information,
particularly to assess the influence of adjuvant hormonal
treatment on risk of developing CBC after HR-positive
FBC. However, we assume that almost all women with
HR-positive FBC received adjuvant hormone treatment
based on the introduction of treatment with tamoxifen
in German guidelines in 1995. Available German study
results underline this assumption [23]. Finally, misclassi-
fication of HR status by differences in for example tissue
fixation, choice of antibody, scoring method and type of
assay could have affected SIRs. Several reports docu-
mented an interobserver and interlaboratory variation
for radioimmunoassay and immunohistochemical assay
[31,32]. The HR status of the analyzed cases was pre-
dominantly determined by immunostains.
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HR status and age at diagnosis of breast cancer are
modifiers for risk of CBC. Women with HR-negative
FBC have an increased risk of all HR subtypes in CBC,
and specifically of HR-negative. Our findings support,
among these women with age lower than 50 years at
FBC diagnosis, the recommendation of intensive follow-
up and surveillance for secondary prevention of cancer in
the contralateral breast.
Additional file
Additional file 1: Pooling Brandenburg, Munich and Saarland,
1998-2007. Table S1. Shows standardized incidence ratios of
metachronous contralateral breast cancer stratified by estrogen receptor
(ER)-status. Table S2. Shows standardized incidence ratios of
metachronous contralateral breast cancer stratified by hormone receptor
(HR)-status excluding cases with missing HR status.
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